Abstract: The present invention relates to novel compounds containing CF3O end groups, to the use thereof as surface-active substances, and to processes for the preparation of these compounds.
Type:
Application
Filed:
June 27, 2009
Publication date:
May 19, 2011
Applicant:
Merck Patent Gesellschaft Mit Beschrankterhaftung
Inventors:
Wolfgang Hierse, Eckhard Claus, Melanie Kleineidam, Peer Kirsch, Elvira Montenegro, Martin Seidel
Abstract: Isolated nucleic acids encoding an allergen of Dermatophagoides pteronyssinus, Der p III, are disclosed. A cDNA encoding a peptide having a Der p III activity and a predicted molecular weight of about 24,985 daltons is also described. The nucleic acids can be used as probes to detect the presence of Der p III nucleic acid in a sample or for the recombinant production of peptides having an activity of Der p III. Peptides having an activity of Der p III can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to house dust mites.
Type:
Application
Filed:
January 15, 2010
Publication date:
May 19, 2011
Applicant:
MERCK PATENT GmbH
Inventors:
Wayne R. THOMAS, Kaw-Yan Chua, Bruce L. Rogers, Mei-chang Kuo
Abstract: The invention relates to compounds of the formula (I), to the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumours and/or diseases in the development or course of which kinases are involved.
Type:
Grant
Filed:
November 28, 2006
Date of Patent:
May 17, 2011
Assignee:
Merck Patent GmbH
Inventors:
Melanie Schultz, Lars Thore Burgdorf, Dirk Finsinger, Andree Blaukat, Hartmut Greiner, Christina Esdar
Abstract: Novel thienopyridine derivatives of the formula (I), in which R1, R2, R3 and Y have the meanings indicated in claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
Abstract: The invention relates to complexes of certain flavonoid derivatives, of the formula (I), where R1 and R2 are selected from H and OR11, where OR11 stands, independently of one another, for OH, straight-chain or branched C1- to C20-alkoxy groups, straight-chain or branched C3- to C20-alkenyloxy groups, straight-chain or branched C1- to C20-hydroxyalkoxy groups, where the hydroxyl group(s) may be bonded to a primary or secondary carbon atom in the chain and furthermore the alkyl chain may also be interrupted by oxygen, and/or C3- to C10-cycloalkoxy groups and/or C3- to C12-cycloalkenyloxy groups, where the rings may in each case also be bridged by —(CH2)n— groups, where n=1 to 3, and/or mono- and/or oligoglycosyl radicals, with the proviso that at least one radical from R1 and R2 stands for OR11, and R3 to R10 may be identical or different and stand, independently of one another, for radicals which are substantially inert with respect to the UV properties, to compositions which comprise such complexes, to corres
Type:
Grant
Filed:
November 3, 2005
Date of Patent:
May 17, 2011
Assignee:
Merck Patent Gesellschaft mit beschrankter Haftung
Inventors:
Christophe Carola, Anne Toullec, Herwig Buchholz
Abstract: The invention relates to chiral compounds, methods of their preparation, and to their use in optical, electrooptical, electronic, semiconducting or luminescent components or devices, and in decorative, security, cosmetic or diagnostic applications.
Type:
Grant
Filed:
March 16, 2007
Date of Patent:
May 17, 2011
Assignee:
Merck Patent Gesellschaft mit beschrankter Haftung
Inventors:
Louise Diane Farrand, Patricia Eileen Saxton
Abstract: The present invention is directed to novel substituted fused aminopiperidines of structural formula (I) which are inhibitors of the dipeptidyl peptidase-4 enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-4 enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-4 enzyme is involved.
Type:
Grant
Filed:
December 8, 2006
Date of Patent:
May 17, 2011
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Jason M. Cox, Scott D. Edmondson, Anthony Mastracchio
Abstract: The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
Type:
Grant
Filed:
October 24, 2008
Date of Patent:
May 17, 2011
Assignee:
Merck Frosst Canada Ltd.
Inventors:
Anh Chau, Bernard Cote, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Andre Giroux, Evelyn Martins, Hongping Yu, Tom Wu
Abstract: This invention relates to a new method for improving functional protein expression whereby the folding process is monitored by online measurement and, if required, the protein folding is influenced by adding folding promoting agents and/or co-expression of the periplasmic chaperone (Skp). In this respect, the invention offers a technology to improve the yield of functionally expressed recombinant proteins.
Type:
Grant
Filed:
July 3, 2002
Date of Patent:
May 17, 2011
Assignee:
Merck Patent GmbH
Inventors:
Uwe Horn, Ulrike Riesenberg, Wolfgang Strittmatter
Abstract: The present invention relates to electroluminescent polymers which comprise 2-vinylthiophenylbenzene derivatives as recurring units, to a process for the preparation thereof, to blends and formulations comprising these polymers, and to the use of these polymers in electronic devices, in particular in organic light-emitting diodes, so-called OLEDs.
Abstract: The present invention relates to organic electroluminescent devices which comprise ketone or phosphine oxide derivatives as matrix material and at least two phosphorescent compounds.
Type:
Application
Filed:
November 18, 2009
Publication date:
May 12, 2011
Applicant:
Merck Patent GmbH
Inventors:
Joachim Kaiser, Arne Buesing, Anja Gerhard, Philipp Stoessel, Susanne Heun
Abstract: The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
Abstract: One aspect of the invention generally relates to use of tissue enriched miRNAs as biomarker to estimate tissue damage in a fluid sample. In a second aspect, methods are provided for monitoring a subject who is exposed or might have been exposed to an agent that has a risk of causing tissue injury. In a third aspect, methods are provided for identifying an agent as having a risk of causing tissue injury to a vertebrate subject. In a fourth aspect, kits are provided for practicing the methods of above-listed aspects. The contents of this ABSTRACT are not intended to in anyway limit the scope of the inventions claimed herein.
Type:
Application
Filed:
April 24, 2009
Publication date:
May 12, 2011
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Thomas L. Fare, Philip W. Garrett-Engele, Warren E. Glaab, Jason M. Johnson, Omar F. Laterza, Lee Lim, Steve W. Ludmerer, David B. Olsen, Joseph F. Sina, Frank D. Sistare
Abstract: The present invention relates to aromatic amines and to electronic devices in which these amines are used, in particular, as matrix material in the emitting layer and/or as hole-transport material and/or as electron-blocking or exciton-blocking material and/or as electron-transport material.
Type:
Application
Filed:
September 10, 2009
Publication date:
May 12, 2011
Applicant:
MERCK PATENT GMBH
Inventors:
Philipp Stoessel, Holger Heil, Dominik Joosten, Christof Pflumm, Anja Gerhard
Abstract: The invention relates to the use of a multi-nuclear metal or transition metal complex in an organic electronic device, said complex having a small ?E spacing, particularly between 50 cm?1 and 2000 cm?1, between the lowest triplet state and the singlet state that is higher and is achieved by thermal backfilling from the triplet. The invention further relates to the use of the strong absorptions of such multinuclear metal complexes, particularly in OSCs.
Abstract: The present invention relates to transition-metal complexes of the general formula I or II, in particular as emitter molecules in organic electronic devices, to a layer and to an electronic device which comprise the compounds according to the invention, and to a process for the preparation of the compounds according to the invention.
Type:
Application
Filed:
October 14, 2009
Publication date:
May 12, 2011
Applicant:
Merck Patent GmbH
Inventors:
Amir Hossain Parham, Arne Buesing, Anja Gerhard, Joachim Kaiser, Rocco Fortte
Abstract: The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
Type:
Application
Filed:
January 18, 2011
Publication date:
May 12, 2011
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
James C. Barrow, Kelly-Ann S. Bieber, Rowena V. Cube, Mamio Christa Mattern, Thomas S. Reger, Youheng Shu, Zhi-Qiang Yang
Abstract: The present invention relates to condensed aromatic compounds with multiple ring bridging of the general formulae (1), (2), (3), (4) and (5). The invention furthermore relates to the use of the compounds according to the invention in an organic electronic device and to a process for the preparation of the compounds according to the invention. The invention furthermore relates to an electronic device which comprises the compounds according to the invention.
Type:
Application
Filed:
October 1, 2009
Publication date:
May 12, 2011
Applicant:
Merck Patent GmbH
Inventors:
Amir Hossain Parham, Christof Pflumm, Holger Heil, Arne Buesing
Abstract: The invention relates to a method for the liquid-liquid extraction of alcohols from aqueous solutions using at least one ionic liquid containing a tricyanomethide anion as solvent.
Type:
Application
Filed:
May 28, 2009
Publication date:
May 12, 2011
Applicant:
MERCK PATENT GESELLSCHAFT
Inventors:
William-Robert Pitner, Emil Ferdinand Aust, Michael Schulte, Uschi Schmid-Grossmann